Compare FSLY & SVRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FSLY | SVRA |
|---|---|---|
| Founded | 2011 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.1B |
| IPO Year | 2019 | N/A |
| Metric | FSLY | SVRA |
|---|---|---|
| Price | $18.38 | $5.60 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 7 | 9 |
| Target Price | ★ $11.67 | $7.33 |
| AVG Volume (30 Days) | ★ 12.2M | 1.4M |
| Earning Date | 02-11-2026 | 03-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $624,018,000.00 | N/A |
| Revenue This Year | $9.16 | N/A |
| Revenue Next Year | $7.44 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 14.78 | N/A |
| 52 Week Low | $4.65 | $1.89 |
| 52 Week High | $19.14 | $7.01 |
| Indicator | FSLY | SVRA |
|---|---|---|
| Relative Strength Index (RSI) | 82.36 | 56.95 |
| Support Level | $7.87 | $5.10 |
| Resistance Level | $17.86 | $5.44 |
| Average True Range (ATR) | 0.95 | 0.34 |
| MACD | 0.79 | 0.04 |
| Stochastic Oscillator | 87.20 | 91.62 |
Fastly operates a content delivery network, which is necessary for entities to provide faster and more reliable online content. Fastly's strategy differs from traditional CDNs, which focus on locating servers in as many locations as possible to store copies of files that consumers most use. Fastly is in far fewer sites than traditional CDNs, but it houses servers in the most network-dense data centers. Instead of simply storing static content, it allows its customers to program on its platform, enabling edge computing and better service of the more dynamic content that was traditionally not well served by CDNs. Fastly gears its service to the largest, most sophisticated enterprises rather than small companies and generated nearly three fourths of its revenue in the United States in 2024.
Savara Inc is a biopharmaceutical company. It is focused on rare respiratory diseases. The company's program, molgramostim nebulizer solution (molgramostim), is an inhaled granulocyte-macrophage colony-stimulating factor in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). It has one segment specialty pharmaceuticals within the respiratory system.